Literature DB >> 3179165

Effect of the removal of individual antiepileptic drugs on antipyrine kinetics, in patients taking polytherapy.

P N Patsalos1, J S Duncan, S D Shorvon.   

Abstract

1. Antipyrine (AP) clearance, half-life and volume of distribution were determined in 52 patients, taking one or more antiepileptic drug (AED), before and 4 weeks after the complete removal of phenytoin (PHT, n = 20), carbamazepine (CBZ, n = 15) and sodium valproate (VPA, n = 17). 2. PHT removal was associated with a mean 13% fall in AP clearance and a mean 16% increase in AP half-life, in patients who were also taking CBZ with or without barbiturates. There was no significant difference between patients who did, and did not, take barbiturates, in addition to CBZ. 3. CBZ removal was associated with a mean 45% fall in AP clearance and a mean 69% increase in AP half-life, if there was no inducing AED comedication, but had no effect on AP clearance and half-life if PHT and/or barbiturates were also being taken. 4. Removal of VPA had no effect on AP clearance or half-life. 5. The removal of PHT, CBZ and VPA had no significant effect on AP volume of distribution. 6. PHT appears to be a more powerful inducer of hepatic enzyme activity, as measured by the AP test, than is CBZ.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3179165      PMCID: PMC1386536          DOI: 10.1111/j.1365-2125.1988.tb05274.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  19 in total

1.  Lack of hepatic enzyme inducing effect of sodium valproate.

Authors:  J Oxley; A Hedges; K A Makki; A Monks; A Richens
Journal:  Br J Clin Pharmacol       Date:  1979-08       Impact factor: 4.335

2.  Effect of diphenylhydantoin on hepatic drug hydroxylation.

Authors:  F Petruch; R V Schüppel; G Steinhilber
Journal:  Eur J Clin Pharmacol       Date:  1974-07-26       Impact factor: 2.953

Review 3.  Assessment of the drug metabolism capacity of the liver.

Authors:  B K Park
Journal:  Br J Clin Pharmacol       Date:  1982-11       Impact factor: 4.335

4.  A comparative study of antipyrine and lignocaine disposition in normal subjects and in patients treated with enzyme-inducing drugs.

Authors:  E Perucca; A Hedges; K A Makki; A Richens
Journal:  Br J Clin Pharmacol       Date:  1980-11       Impact factor: 4.335

5.  Microsomal enzyme induction in children: the influence of carbamazepine treatment on antipyrine kinetics, 6 beta-hydroxycortisol excretion and plasma gamma-glutamyltranspeptidase activity.

Authors:  T A Moreland; B K Park; G W Rylance
Journal:  Br J Clin Pharmacol       Date:  1982-12       Impact factor: 4.335

6.  Valproic acid and plasma levels of phenobarbital.

Authors:  J Bruni; B J Wilder; R J Perchalski; E J Hammond; H J Villarreal
Journal:  Neurology       Date:  1980-01       Impact factor: 9.910

7.  Time-course of interaction between carbamazepine and clonazepam in normal man.

Authors:  A A Lai; R H Levy; R E Cutler
Journal:  Clin Pharmacol Ther       Date:  1978-09       Impact factor: 6.875

8.  Mechanism of valproate-phenobarbital interaction in epileptic patients.

Authors:  I M Kapetanović; H J Kupferberg; R J Porter; W Theodore; E Schulman; J K Penry
Journal:  Clin Pharmacol Ther       Date:  1981-04       Impact factor: 6.875

9.  Comparison of the in vivo and in vitro rates of formation of the three main oxidative metabolites of antipyrine in man.

Authors:  A R Boobis; M J Brodie; G C Kahn; E L Toverud; I A Blair; S Murray; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1981-12       Impact factor: 4.335

10.  Dual effects of carbamazepine-phenytoin interaction.

Authors:  J J Zielinski; D Haidukewych
Journal:  Ther Drug Monit       Date:  1987       Impact factor: 3.681

View more
  9 in total

Review 1.  Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants.

Authors:  K Wilbur; M H Ensom
Journal:  Clin Pharmacokinet       Date:  2000-04       Impact factor: 6.447

Review 2.  Antiepileptic-induced resistance to neuromuscular blockers: mechanisms and clinical significance.

Authors:  Sulpicio G Soriano; J A Jeevendra Martyn
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

3.  The use of microdialysis for the study of drug kinetics: some methodological considerations illustrated with antipyrine in rat frontal cortex.

Authors:  P N Patsalos; W T Abed; M S Alavijeh; M T O'Connell
Journal:  Br J Pharmacol       Date:  1995-06       Impact factor: 8.739

4.  Dose dependent enzyme induction by oxcarbazepine?

Authors:  P N Patsalos; J M Zakrzewska; A A Elyas
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 5.  Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations.

Authors:  M Barry; S Gibbons; D Back; F Mulcahy
Journal:  Clin Pharmacokinet       Date:  1997-03       Impact factor: 6.447

6.  Effects of valproate on xenobiotic biotransformation in rat liver. In vivo and in vitro experiments.

Authors:  V Rogiers; A Callaerts; A Vercruysse; M Akrawi; E Shephard; I Phillips
Journal:  Pharm Weekbl Sci       Date:  1992-06-19

Review 7.  Antiepileptic drugs. A review of clinically significant drug interactions.

Authors:  P N Patsalos; J S Duncan
Journal:  Drug Saf       Date:  1993-09       Impact factor: 5.606

Review 8.  Cardiometabolic effects of psychotropic medications.

Authors:  Oluchi Abosi; Sneha Lopes; Samantha Schmitz; Jess G Fiedorowicz
Journal:  Horm Mol Biol Clin Investig       Date:  2018-01-10

9.  Discontinuation of carbamazepine due to concerns of long-term consequences of enzyme induction.

Authors:  Jussi Mäkinen; Sirpa Rainesalo; Jani Raitanen; Jukka Saarinen; Satu Sandell; Jukka Peltola
Journal:  Epilepsia Open       Date:  2018-06-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.